The Economic Impact of Clinical Pharmacist Involvement in the Public Procurement for Medicines and in the Drug and Therapeutics Committee

The Economic Impact of Clinical Pharmacist Involvement in the Public Procurement for Medicines and in the Work of the Drug and Therapeutics Committee, Single-centre, Cost-minimisation Study

The investigators have performed cost-minimisation analysis and compared the expenses based on the plan for public procurement (without clinical pharmacist involvement) for drugs with the results of public procurement based on the revised plan for public procurement by the clinical pharmacist. The plan for public procurements was based on the 1 year quantity for each medicine used by the hospital in the previous year, based on the latest deliverable prices at the time of extracting the data to workbook for MS Excel program (ver. 2002, Microsoft, Redmond, WA, USA).

The investigators have performed cost-minimisation analysis and compared the expenses for all received requests for medicines to the drug and therapeutics committee (DTC) for a decision in the 1 year period, before and after involvement of clinical pharmacist in the committee work. The expenses were based on approval decisions in the 1 year period for approval time period. The denial decisions were also calculated and reported. The denial period calculated in rationalisation of expenses were based on 1 year treatment period.

Study Overview

• Status: Completed
• Conditions: Rationalization
• Intervention / Treatment: Drug: Public procurement; Drug: Drug and Therapeutics Committee

• Study Type: Observational
• Enrollment (Actual): 10000

Contacts and Locations

Study Locations

• Croatia
  • Bjelovar, Croatia, 43000
    • General Hospital Bjelovar

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 1 year to 100 years (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Inhospital patients, all patients receiving any medicine during their stay in the hospital within 1 year period.

Description

Inclusion Criteria:

• All patients in the hospital (inhospital patients)

Exclusion Criteria:

• None

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Reducing prices of medicines	Reduce prices of medicines in percentage, since different countries and hospitals have various budgets and medicine prices	1 year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Rationalization of expenses	Rationalization of expenses through rquests for medicines sent to Drug and Therapeutics Committee	1 year

Collaborators and Investigators

• Sponsor: Bjelovar General Hospital

Study record dates

Study Major Dates

• Study Start (Actual): August 1, 2019
• Primary Completion (Actual): May 1, 2020
• Study Completion (Actual): June 1, 2020

Study Registration Dates

• First Submitted: March 17, 2020
• First Submitted That Met QC Criteria: March 17, 2020
• First Posted (Actual): March 19, 2020

Study Record Updates

• Last Update Posted (Actual): December 17, 2020
• Last Update Submitted That Met QC Criteria: December 16, 2020
• Last Verified: December 1, 2020

More Information

Terms related to this study

• Keywords: Clinical Pharmacist; Rationalization; Public Procurement for Medicines; Drug and Therapeutics Committee
• Additional Relevant MeSH Terms: Dermatologic Agents; Keratolytic Agents; Coal Tar
• Other Study ID Numbers: 1520192020

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No